Perioperative Management and Outcomes of Preoperatively Diagnosed Venous Thromboembolism in Gynecological Surgery: A Multicenter Retrospective Study Based on 2020-2022 Data From the Japanese Society of Anesthesiologists.
OA: closed
Abstract
AimPatients with preoperatively diagnosed venous thromboembolism (VTE) present complex management challenges, and optimal strategies for gynecological surgery remain unclear. Because malignancy is a major risk factor for VTE, perioperative management and outcomes may differ between malignant and benign gynecological diseases. This study aimed to compare perioperative management and short-term outcomes between these groups.MethodsThis retrospective observational study included 1406 patients with preoperatively diagnosed VTE undergoing gynecological surgery between 2020 and 2022 using the Japanese Society of Anesthesiologists database. Patients were divided into malignant (M-group, n = 1126) and benign (B-group, n = 280) groups. Clinical characteristics, treatment strategies, and postoperative outcomes within 28 days after surgery were compared.ResultsOf 1406 patients, 421 (29.9%) had pulmonary embolism, 161 (11.5%) had proximal deep vein thrombosis (DVT), and 824 (58.6%) had distal DVT. Direct oral anticoagulants were the most commonly used preoperative anticoagulants (61.3%), followed by unfractionated heparin (24.8%). Postoperative anticoagulation was more frequent in the M-group than in the B-group (57.5% vs. 44.6%; p < 0.001). The 28-day all-cause mortality (1.2% vs. 0.7%; p = 0.752), VTE recurrence (2.0% vs. 2.9%; p = 0.406), and major bleeding (1.1%; p = 0.220) were comparable between groups.ConclusionsThis study provides real-world data on perioperative management and short-term outcomes in gynecological surgical patients with preoperatively diagnosed VTE in Japan. Prospective studies are required to establish optimal, risk-stratified perioperative management strategies.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
SciLite annotations
chemicals 9
heparin
heparin
warfarin
fondaparinux
fondaparinux
dabigatran
rivaroxaban
apixaban
edoxaban
Source provenance
- europepmc
- last seen: 2026-09-20T09:27:46.357103+00:00
- scilite
- last seen: 2026-09-13T09:58:29.948030+00:00
- unpaywall
- last seen: 2026-09-22T06:12:16.469521+00:00